Research on clinical development of a new clinical outcome (major pathological response) for preoperative treatment of lung cancer using artificial intelligence

A single-center, backward-looking observational study on "Clinical development of a new endpoint of major pathological response for preoperative treatment of lung cancer using artificial intelligence and a digital pathology platform" - A single-center, backward-looking observational study on "Clinical development of a new endpoint of major pathological response for preoperative treatment of lung cancer using artificial intelligence and a digital pathology platform"

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047486

Enrollment

Registered

2022-05-09

Start date

2022-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer patients who received preoperative treatment at our hospital from April 2002 to April 2021 and subsequently underwent surgery

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-small cell lung cancer patients who received preoperative treatment at our hospital from April 2002 to April 2021 and subsequently underwent surgery and for whom FFPE block of the surgical specimen is available

Exclusion criteria

Exclusion criteria: There are no specific exclusion criteria.

Design outcomes

Primary

Measure	Time frame
Relationship between PR and MPR evaluated by artificial intelligence and MPR and PR evaluated by pathologists	—

Countries

Japan

Contacts

Public ContactAkira Ono

Shizuoka Cancer Center Division of Thoracic Oncology

a.ono@scchr.jp055-989-5222

Outcome results